Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Jose Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gomez, Phuong Dinh, Karine Kauria, Veerie Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horvath, Maria Coccia-Portugal, Julien Domont, Ling-Min Tseng, Georg Gunz, Joo Hyuk Sohn, Vladimir Semiglazov & 4 others Guillermo Lerzo, Marketa Palacova, Volodymur Probachai, Lajos Pusztai

    Research output: Contribution to journal › Article

    813 Citations (Scopus)
    LanguageEnglish
    Pages663-640
    JournalThe Lancet
    Volume379
    Issue number9816
    DOIs
    Publication statusPublished - 2012

    Cite this

    Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., ... Pusztai, L. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet, 379(9816), 663-640. https://doi.org/10.1016/S0140-6736(11)61847-3
    Baselga, Jose ; Bradbury, Ian ; Eidtmann, Holger ; Di Cosimo, Serena ; de Azambuja, Evandro ; Aura, Claudia ; Gomez, Henry ; Dinh, Phuong ; Kauria, Karine ; Van Dooren, Veerie ; Aktan, Gursel ; Goldhirsch, Aron ; Chang, Tsai-Wang ; Horvath, Zsolt ; Coccia-Portugal, Maria ; Domont, Julien ; Tseng, Ling-Min ; Gunz, Georg ; Hyuk Sohn, Joo ; Semiglazov, Vladimir ; Lerzo, Guillermo ; Palacova, Marketa ; Probachai, Volodymur ; Pusztai, Lajos. / Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. In: The Lancet. 2012 ; Vol. 379, No. 9816. pp. 663-640.
    @article{4631419bc91847438444c0c62966e457,
    title = "Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial",
    author = "Jose Baselga and Ian Bradbury and Holger Eidtmann and {Di Cosimo}, Serena and {de Azambuja}, Evandro and Claudia Aura and Henry Gomez and Phuong Dinh and Karine Kauria and {Van Dooren}, Veerie and Gursel Aktan and Aron Goldhirsch and Tsai-Wang Chang and Zsolt Horvath and Maria Coccia-Portugal and Julien Domont and Ling-Min Tseng and Georg Gunz and {Hyuk Sohn}, Joo and Vladimir Semiglazov and Guillermo Lerzo and Marketa Palacova and Volodymur Probachai and Lajos Pusztai",
    year = "2012",
    doi = "10.1016/S0140-6736(11)61847-3",
    language = "English",
    volume = "379",
    pages = "663--640",
    journal = "Lancet",
    issn = "0140-6736",
    publisher = "Elsevier",
    number = "9816",

    }

    Baselga, J, Bradbury, I, Eidtmann, H, Di Cosimo, S, de Azambuja, E, Aura, C, Gomez, H, Dinh, P, Kauria, K, Van Dooren, V, Aktan, G, Goldhirsch, A, Chang, T-W, Horvath, Z, Coccia-Portugal, M, Domont, J, Tseng, L-M, Gunz, G, Hyuk Sohn, J, Semiglazov, V, Lerzo, G, Palacova, M, Probachai, V & Pusztai, L 2012, 'Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial', The Lancet, vol. 379, no. 9816, pp. 663-640. https://doi.org/10.1016/S0140-6736(11)61847-3

    Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. / Baselga, Jose; Bradbury, Ian; Eidtmann, Holger; Di Cosimo, Serena; de Azambuja, Evandro; Aura, Claudia; Gomez, Henry; Dinh, Phuong; Kauria, Karine; Van Dooren, Veerie; Aktan, Gursel; Goldhirsch, Aron; Chang, Tsai-Wang; Horvath, Zsolt; Coccia-Portugal, Maria; Domont, Julien; Tseng, Ling-Min; Gunz, Georg; Hyuk Sohn, Joo; Semiglazov, Vladimir; Lerzo, Guillermo; Palacova, Marketa; Probachai, Volodymur; Pusztai, Lajos.

    In: The Lancet, Vol. 379, No. 9816, 2012, p. 663-640.

    Research output: Contribution to journal › Article

    TY - JOUR

    T1 - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

    AU - Baselga, Jose

    AU - Bradbury, Ian

    AU - Eidtmann, Holger

    AU - Di Cosimo, Serena

    AU - de Azambuja, Evandro

    AU - Aura, Claudia

    AU - Gomez, Henry

    AU - Dinh, Phuong

    AU - Kauria, Karine

    AU - Van Dooren, Veerie

    AU - Aktan, Gursel

    AU - Goldhirsch, Aron

    AU - Chang, Tsai-Wang

    AU - Horvath, Zsolt

    AU - Coccia-Portugal, Maria

    AU - Domont, Julien

    AU - Tseng, Ling-Min

    AU - Gunz, Georg

    AU - Hyuk Sohn, Joo

    AU - Semiglazov, Vladimir

    AU - Lerzo, Guillermo

    AU - Palacova, Marketa

    AU - Probachai, Volodymur

    AU - Pusztai, Lajos

    PY - 2012

    Y1 - 2012

    U2 - 10.1016/S0140-6736(11)61847-3

    DO - 10.1016/S0140-6736(11)61847-3

    M3 - Article

    VL - 379

    SP - 663

    EP - 640

    JO - Lancet

    T2 - Lancet

    JF - Lancet

    SN - 0140-6736

    IS - 9816

    ER -

    Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2012;379(9816):663-640. https://doi.org/10.1016/S0140-6736(11)61847-3

    Access to Document